Voriconazole for IPA in Chinese Patients With COPD

• Status: Unknown status
• Trial end date: 2016-12-01
• Target enrollment: 0
• Participant gender: All

Summary

voriconazole is recommended as first-line therapy for invasive pulmonary aspergillosis, however the efficacy and safety of voriconazole for treating invasive pulmonary aspergillosis secondary to COPD is not clear. This study aims to investigate the effectiveness and tolerability of intravenous voriconazole for treatment of invasive pulmonary aspergillosis in Chinese patients with COPD, by monitoring changes in clinical symptoms, eradication of aspergillus, improvement of chest imaging as well as record of possible adverse reactions following 2-week intravenous instillation of voriconazole.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Red Cross Hospital, Hangzhou, China
• Collaborators: First People's Hospital Affiliated to Huzhou University; First People's Hospital of Hangzhou; Hangzhou Hospital of Traditional Chinese Medicine; Ningbo People's Hospital; Second People's Hospital of Hangzhou; Sir Run Run Shaw Hospital; Xiaoshan Hospital; Xiaoshan People's Hospital; Zhejiang Provincial People's Hospital; Zhejiang Provincial People’s Hospital
• Treatments: Voriconazole

Criteria

Inclusion Criteria:

• Cases of invasive pulmonary aspergillosis secondary to COPD

Exclusion Criteria:

• Use of voriconazole or itraconazole or amphotericin B or caspofungin or micafungin within 4 weeks prior to enrollment

• Known allergy to voriconazole

• Severe impairment of live or kidney function

• Septic shock

• Unwilling to sign informed consent